CAS 1020172-07-9

Rebastinib

Description:

Rebastinib is a small molecule inhibitor primarily known for its role in targeting specific kinases involved in cancer cell signaling pathways. It is particularly noted for its activity against the ABL and SRC family of kinases, which are implicated in various malignancies, including chronic myeloid leukemia and solid tumors. The compound is characterized by its ability to disrupt the phosphorylation processes that drive tumor growth and survival, making it a candidate for therapeutic applications in oncology. Rebastinib has been studied in clinical trials, showcasing its potential to inhibit tumor progression and improve patient outcomes. Its chemical structure includes specific functional groups that contribute to its binding affinity and selectivity for its targets. As with many investigational drugs, ongoing research is focused on optimizing its efficacy, understanding its pharmacokinetics, and evaluating its safety profile in diverse patient populations. Overall, Rebastinib represents a promising avenue in targeted cancer therapy, reflecting the broader trend of developing precision medicines in oncology.

Formula: C₃₀H₂₈FN₇O₃

Synonyms:

• N-[3-tert-Butyl-1-(quinolin-6-yl)-1H-pyrazol-5-yl]-N'-[2-fluoro-4-[(2-(methylcarbamoyl)pyridin-4-yl)oxy]phenyl]urea
• Dcc-2036
• N-[3-tert-Butyl-1-(quinolin-6-yl)-1H-pyrazol-5-yl]-N'-[2-fluoro-4-[(2-(MethylcarbaMoyl)pyridin-4-yl)
• N-[3-tert-Butyl-1-(quinolin-6-yl)-1H-pyrazol-5-yl]-N'-[2-fluoro-4-[(2-(methylcarbamoyl)pyridin-4-yl)oxy]phenyl]urea DCC-2036 (Rebastinib)
• 2-Pyridinecarboxamide, 4-[4-[[[[3-(1,1-dimethylethyl)-1-(6-quinolinyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-
• DCC-2036 (Rebastinib)
• Rebastinib(DCC-2036)
• Rebastinib Tosylate
• DCC2036;DCC 2036
• 1-(3-tert-butyl-1-(quinolin-6-yl)-1H-pyrazol-5-yl)-3-(2-fluoro-4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenyl)urea
• N-[3-tert-Butyl-1-(quinolin-6-yl)-1H-pyrazol-5-yl]-N'-[2-fluoro-4-[(2-(methylcarbamoyl)pyridin-4-yl)oxy]phenyl]urea USP/EP/BP
• DCC2036; DCC-2036; DCC 2036; REBASTINIB.
• CS-1867
• 4-(4-(3-(3-(tert-Butyl)-1-(quinolin-6-yl)-1H-pyrazol-5-yl)ureido)-3-fluorophenoxy)-N-methylpic
• 4-[4-[(5-tert-butyl-2-quinolin-6-ylpyrazol-3-yl)carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide
• Rebastinib

N-[3-tert-Butyl-1-(quinolin-6-yl)-1H-pyrazol-5-yl]-N'-[2-fluoro-4-[(2-(methylcarbamoyl)pyridin-4-yl)oxy]phenyl]urea

CAS: 1020172-07-9

Formula: C₃₀H₂₈FN₇O₃

Purity: 98%

Color and Shape: Solid

Molecular weight: 553.5868

Ref: IN-DA0006BU

4-(4-(3-(3-(Tert-Butyl)-1-(Quinolin-6-Yl)-1H-Pyrazol-5-Yl)Ureido)-3-Fluorophenoxy)-N-Methylpicolinamide

CAS: 1020172-07-9

4-(4-(3-(3-(Tert-Butyl)-1-(Quinolin-6-Yl)-1H-Pyrazol-5-Yl)Ureido)-3-Fluorophenoxy)-N-Methylpicolinamide

Purity: 98%

Molecular weight: 553.59g/mol

Ref: 54-PC108457

Rebastinib

CAS: 1020172-07-9

Rebastinib

Purity: ≥98%

Molecular weight: 553.59g/mol

Ref: 54-BUP10073

Rebastinib

CAS: 1020172-07-9

DCC-2036 (Rebastinib (DCC-2036)) is a conformational control Bcr-Abl inhibitor for Abl1(WT, IC50: 0.8 nM) and Abl1(T315I, IC50: 4 nM), also inhibits LYN, SRC,

Formula: C₃₀H₂₈FN₇O₃

Purity: 99.53% - 99.79%

Color and Shape: Solid

Molecular weight: 553.59

Ref: TM-T2640

DCC 2036

CAS: 1020172-07-9

Inhibits multiple tyrosine kinases (Abl1, Src family kinases, Tie-2 and VEGFR-2)

Formula: C₃₀H₂₈FN₇O₃

Purity: Min. 95%

Color and Shape: Powder

Molecular weight: 553.59 g/mol

Ref: 3D-FD64998